CJC-1295 (with DAC) | 2mg & 5mg
Technical Specifications
- Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH2
- Chemical Name: DAC:GRF (Drug Affinity Complex Growth Hormone Releasing Factor)
- Format: Lyophilised Cake/Powder
- Purity: >99% (HPLC Verified)
- Half-Life: Extended (approx. 6–8 days)
- Solubility: High (Aqueous)
- Solvent: Solvent not included (Sold Separately)
- Grade: Analytical Research Grade
Variant Breakdown
- 2mg Vial: Standard research aliquot.
- 5mg Vial: High-Concentration Vial.
- Note: All variants are contained within a 3ml capacity vial.
Product Overview
CJC-1295 (with DAC) is a long-acting synthetic analogue of Growth Hormone Releasing Hormone (GHRH).
While it shares the same core amino acid sequence as "Mod GRF 1-29," this specific variant is modified with a Drug Affinity Complex (DAC)—specifically, a maleimidopropionic acid group attached to the Lysine residue at the C-terminus.
The "DAC" Mechanism:
This chemical modification allows the peptide to covalently bind to circulating serum albumin after administration. By "hitching a ride" on albumin, the peptide is protected from enzymatic degradation and renal filtration. This extends its biological half-life from minutes to 6–8 days.
Unlike the "No DAC" version (which creates natural pulses), CJC-1295 with DAC is researched for its ability to provide continuous, basal stimulation of the pituitary gland. This results in a sustained elevation of mean GH and IGF-1 levels, making it the primary reagent for research requiring steady-state hormonal output rather than pulsatile signaling.
Quality Assurance
This compound has undergone rigorous third-party analysis.
- HPLC Verified: Independent analysis confirms peptide purity exceeds 99%.
- Mass Spectrometry: Confirms the presence of the maleimidopropionic acid (DAC) group.
- TFA Removal: Processed via acetate exchange to ensure cellular viability.
Research Mechanism
In laboratory settings, CJC-1295 (with DAC) is utilised to investigate:
- Sustained IGF-1 Elevation: Studies demonstrating massive increases in total weekly IGF-1 production due to the lack of "troughs" in GH secretion.
- Lipolysis via GH Bleed: Researching the effects of constant GH presence on free fatty acid mobilisation (the "GH Bleed" effect).
- Pituitary Load: Investigating the long-term effects of continuous GHRH receptor activation on somatotroph desensitisation.
Safety and Handling
WARNING: This product is exclusively for laboratory research and in vitro use.
- Research Only: Not intended for human consumption, bodybuilding, or therapeutic use.
- Handling: Wear appropriate personal protective equipment (PPE).
Storage: Store lyophilised vials in a cool, dry place. For long-term preservation, freezing at -20°C is recommended.
Scientific References
Journal of Clinical Endocrinology & Metabolism (2006) – "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." (The definitive study comparing DAC pharmacokinetics vs placebo). View Article
Drug Design, Development and Therapy (2015) – "Growth hormone-releasing hormone (GHRH) and its analogues: a review." View Article
Bioconjugate Chemistry (2006) – "Synthesis and albumin binding properties of a maleimide-functionalized GHRH analog." (Detailed chemical analysis of the DAC mechanism). View Article
Neuroendocrinology (2009) – "Pulsatile versus continuous growth hormone secretion: distinct effects on liver and skeletal muscle." (Contextual research on why sustained release matters). View Article
